Abstract Library

#3027 Impact of Small Cell (SC) versus (vs.) Non-Small Cell (nSC) Morphology on Outcomes of Patients (pts) with Extra-Pulmonary, Poorly Differentiated Neuroendocrine Carcinoma (EP-PD-NEC)

Introduction: The 2018 SEER data indicates EP-PD-NEC morphology (SC vs. nSC) may impact patient outcomes.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Zaninotto E

Authors: Zaninotto E, Frizziero M, Durand A, Taboada R, Luchini C,

Keywords: small cell neuroendocrine carcinoma, non small cell neuroendocrine carcinoma, predictive value,

#2265 Activity of Bevacizumab in Neuroendocrine Neoplasms

Introduction: The combination of the anti-VEGF antibody bevacizumab (BEV) with a multitude of other antineoplastic substances has shown promising activity in neuroendocrine neoplasms (NEN). However, data proving the superiority of BEV-containing vs. BEV-free protocols are lacking.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Apostolidis L

Authors: Fejzibegovic N, Jäger D, Winkler E, Apostolidis L,

Keywords: neuroendocrine neoplasm, targeted therapy, bevacizumab, antiangiogenesis,

#1639 Endoscopic Ultrasound Appearance of Pancreatic Serotonin-Staining Neuroendocrine Neoplasms: A Case Series

Introduction: The pancreatic localization of serotonin-staining neuroendocrine neoplasms (serotoninomas) is extremely rare. Less than 350 cases have been reported in the world literature.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Massironi S

Authors: Massironi S, Partelli S, Petrone M, Conte D, Falconi M,

Keywords: pNEN,

#1491 Do Medical Oncology Services Receive More Patients with Neuroendocrine Tumors? Assessment of This Tendency and Reflections About Its Aid Complexity

Introduction: Neuroendocrine tumors meant a change in the clinical practice, multidisciplinary approach (MA) is the gold standard today.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Segura �

Authors: Salvador C, Segura A, Del Olmo M, Niño �, Merino F,

Keywords: Neuroendocrine tumors, epidemiology,

#735 Efficacy of Somatostatin Analogues (SSAs) in Patients with Neuroendocrine Tumors (NETs) According to the 2010 WHO Classification of NET: A Multicentric Study

Introduction: SSAs have recently been demonstrated to have antiproliferative effects in ileal NETs. No data are available on SSA efficacy according to 2010 WHO NET categories.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Faggiano A, Tafuto S, Riccardi F, Tozzi L, Belfiore A,

Keywords: neuroendocrine tumor, Somatostatin Analogues, efficacy, WHO classification,